Cannabidiol: Food or Drug? A Positioning (Pages 17-24)
Karin Kraft1, Michael Thomsen2 and Mathias Schmidt3
1Centre for Internal Medicine, Medical Faculty of the University of Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany; 2Sydney University Medical School, Discipline of Pharmacology, The University of Sydney, Camperdown NSW 2050, Australia; 3Herbresearch Germany, Wartbergweg 15, 86874 Mattsies, Germany
https://doi.org/10.12970/2308-8044.2021.09.02
Download PDFAbstract: Products containing cannabidiol (CBD) such as CBD oil, are marketed in Europe as food and dietary supplements. They are also frequently advertised as potential treatments for serious illnesses. Applications for Novel Food Status are currently being processed in Europe. On closer scrutiny however, the basis for classifying CBD as a foodstuff is at best, questionable. The use of CBD in the management of severe disease is based on demonstrated pharmacological and clinical effects, which is clearly the domain of drug use. CBD lacks food-typical properties. Although CBD has a high level of toxicological safety even in high doses, this does not imply that it qualifies to be categorised as (novel) food simply because it has been proven to be safe. Herein, we examine the presentation of CBD-containing preparations with the background of European legislation.
Keywords: Cannabidiol, Novel Food, Drug by presentation, narcotics, food supplements.
Read more